Related Experiment Video
Updated: Jun 10, 2026
07:22
Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
Published on: April 11, 2025
Intrahepatic cholangiocarcinoma
George A Poultsides1, Andrew X Zhu, Michael A Choti
1Department of Surgery, Division of Surgical Oncology, Stanford University School of Medicine, 300 Pasteur drive, H3680, Stanford, CA 94305-5641, USA.
The Surgical Clinics of North America
|July 20, 2010
Summary
Intrahepatic cholangiocarcinoma (ICC), a bile duct cancer, is increasing. Surgical resection offers the only potential cure, with adjuvant therapies and locoregional treatments considered for advanced cases.
Area of Science:
- Hepatobiliary cancers
- Gastrointestinal oncology
- Surgical oncology
Background:
- Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer originating from bile duct epithelial cells.
- While uncommon, ICC incidence is rising globally.
- Often detected incidentally as an indeterminate liver mass, early diagnosis is challenging.
Purpose of the Study:
- To review the current understanding and management of intrahepatic cholangiocarcinoma.
- To highlight the role of surgical resection and adjuvant therapies.
- To discuss treatment options for inoperable ICC.
Main Methods:
- Literature review of intrahepatic cholangiocarcinoma management.
- Analysis of surgical resection, lymphadenectomy, and adjuvant treatment roles.
- Evaluation of locoregional therapies for unresectable disease.
Main Results:
- Surgical resection is the only potentially curative treatment for ICC.
- Hilar lymphadenectomy may improve staging accuracy.
- Adjuvant chemotherapy and radiotherapy are considered for node-positive or R1 resection cases.
- Transarterial chemoembolization is an option for inoperable ICC.
Conclusions:
- Multidisciplinary management is crucial for intrahepatic cholangiocarcinoma.
- Optimizing surgical outcomes and considering adjuvant therapies are key.
- Locoregional therapies provide palliative options for advanced disease.
